Skip to content

Methylphenidate

  • Prescription medicine
  • Prescription only
  • Identity checked
  • Sources last checked 2026-09-04

This page shows what was measured, who it was measured in, and what that does not settle.

What Methylphenidate does in the body

Attention Deficit Hyperactivity Disorder

From the FDA-approved label: Methylphenidate HCl is a central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of norepinephrine and dopamine into the presynaptic neuron and increase the release of these monoamines into the extraneuronal space.

What happened in people

RNAWiki has not yet published a reviewed conclusion for this use.

A fixed RNAWiki sentence

Where this came from

Wording RNAWiki always uses, not a finding about this substance.

No reviewed claim names a result for any goal on this record.

No source is stored against this line.

The limit that matters most

Not recorded.

Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

What the registries record it as

  • The substance registry classes this as chemical.

    FDA substance registry · 207ZZ9QZ49 · read 2026-08-29

  • Its recorded molecular formula is C14H19NO2•HCl, weighing 269.77.

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

Where each sentence above came from

No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.

Shown as the opening line on this page.

No statement of the main limit is recorded.

The four opening statements run to 70 words.

Words this page uses

Four words worth knowing first

Chosen from what this page shows, with each one explained before the word it depends on.

Stand-in result

A stand-in result is a number measured because the real result takes too long.

A picture of it, and where the picture fails

It is like judging a journey by the speedometer rather than by arriving.

Where that stops being true. Speed does predict arrival. Many stand-in results do not predict the real one.

What people get wrong. A stand-in result is often reported as the result itself.

A surrogate endpoint substituted for a clinical endpoint, valid only where the substitution has been shown to hold.

Enzyme

An enzyme is a protein that speeds up one chemical change.

A picture of it, and where the picture fails

An enzyme is like a machine on a production line doing one cut.

Where that stops being true. A machine is switched on and off by a person. Enzymes are controlled by the cell.

What people get wrong. Enzymes are thought to be used up. They are not; they work again and again.

A catalytic protein that lowers the activation energy of a specific reaction.

Receptor

A receptor is a part of a cell that a signal fits into.

A picture of it, and where the picture fails

A receptor is like a lock waiting for one key.

Where that stops being true. A lock either opens or does not. A receptor can be half-triggered, or worn out.

What people get wrong. Fitting a receptor is read as causing a benefit. It causes a step, and nothing more.

A protein that binds a specific ligand and converts that binding into a cellular response.

Pathway

A pathway is a chain of steps inside a cell, each one setting off the next.

A picture of it, and where the picture fails

A pathway is like a row of dominoes.

Where that stops being true. Dominoes fall one way. Pathways loop back and can switch themselves off.

What people get wrong. Changing one step is read as changing the outcome. Other steps often absorb it.

An ordered series of molecular interactions producing a defined cellular change.

What happened in peopleRead from sources, not yet reviewed

What was measured, goal by goal

One row for each goal a registered study measured something for. One column for each kind of thing that could be measured.

Registered studies list 40 outcome measures that RNAWiki could read. A registered study says what someone planned to measure. It does not say what they found. 0 of the matched studies tested this substance, and 0 posted a result.

There is no single score. A strong test result and a weak life result are different facts.

Goals down the side, kinds of measurement across the top. Each cell says what kind of thing was registered, not what was found.
GoalLife outcomeWhat a body can doHow a person feelsA test resultA step in the bodyHarmsHow longWho was studied
FocusNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
SleepNothing in the sources checkedNo registered study lists a life outcome for this goal.Nothing in the sources checkedNo registered study lists a performance measure for this goal.Nothing in the sources checkedNo registered study lists a symptom measure for this goal.Nothing in the sources checkedNo registered study lists a test result for this goal.Nothing in the sources checkedNo registered study lists a body-step measure for this goal.Not recordedHarms were not a registered measure for this goal.Not recordedNo finished study window is recorded.Waiting for a reviewerWho was studied is listed further down the page.
Which registered measures put each goal on this table
Focus
cognitive test scores at end of treatment period; wender reimherr adult attention deficit disorder scale
Sleep
sleep latency

Sorted by fixed word lists, version v1. A name the rules do not recognise stays unsorted rather than moving to the nearest column.

What each mark on this table means
Nothing in the sources checked
No registered study lists a life outcome for this goal.
Not recorded
Harms were not a registered measure for this goal.
Waiting for a reviewer
Who was studied is listed further down the page.

What happened in peopleRead from sources, not yet reviewed

What happened in people

Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.

To determine whether the genetic-brain-cognition function markers (or combination of markers) 'normalize' with acute drug treatment in ADHD.

The study did not show it

Who was studied
NCT00863499
How many people
1344
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
What a body can do day to day
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Observed and change from baseline measures for ADHD-RS total scores will be summarized by descriptive statistics and analyzed by repeated measures of analysis of covariance.

The study did not show it

Who was studied
NCT00866996
How many people
1323
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Conners' Global Index - Parent Version (CGI-P)

The study did not show it

Who was studied
NCT00483106
How many people
885
Study design
Phase 4
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Metabolic syndrome score

The study did not show it

Who was studied
NCT01457794
How many people
834
Study design
Not applicable
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Mean Change From Baseline (End of Phase A) in the CAARS-O:SV ADHD Symptoms Total Score (18 Items) to End of Phase B

The study did not show it

Who was studied
NCT01074294
How many people
740
Study design
Phase 2
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot

Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by Treatment

The study did not show it

Who was studied
NCT01259492
How many people
725
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated

What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.

The limits of this study, and where it came from

Main limit. No limitation is recorded for this study.

How far it carries. This study is recorded from the curated record, not from the registry match.

Form and route. Oral

Interval reported. Not recorded in this summary

Written into the record, not signed off as a reviewed claim.

  • openFDA Drugs@FDA · a recorded source, not a stored snapshot
  • openFDA NDC Directory · a recorded source, not a stored snapshot
  • openFDA SPL label · a recorded source, not a stored snapshot
  • PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.

What happened in peopleRead from sources, not yet reviewed

How close this is to real life

The top step is something a person would feel or care about. The bottom is a guess from software. Filled steps are where evidence exists for this substance.

  1. Living longer, or avoiding a major event No evidence recorded. Death, a heart attack, a stroke, a hospital stay.No registered study measures this.
  2. What a body can do day to day No evidence recorded. Walking, dressing, breathing, recovering.No registered study measures this.
  3. Measured performance No evidence recorded. How much was lifted, how far was run, how fast.No registered study measures this.
  4. Symptoms and quality of life Evidence recorded. Pain, tiredness, mood, sleep, as the person rated it.6 registered measures of this kind.
  5. A number that stands in for health Evidence recorded. Cholesterol, blood sugar, bone density. A stand-in, not the thing itself.5 registered measures of this kind.
  6. A step measured inside a person Evidence recorded. Something measured in human tissue or human cells.A human record sits on the stored organism ladder.
  7. Animals Evidence recorded. Mice, rats, dogs. Useful for ideas, not proof about people.Stored records in Mouse. A result in animals says what to test next. It does not say what happens in people.
  8. Cells in a dish No evidence recorded. Cells or chemistry on a bench, far from a whole body.No cell or bench record is stored.
  9. A guess from software No evidence recorded. Nobody measured it. RNAWiki never publishes one as a finding.RNAWiki stores no prediction for this record. Software can suggest a link. RNAWiki does not publish one as a finding.

Higher on these steps means closer to something a person would feel. It does not mean better done.

What it would be like to takeRead from sources, not yet reviewed

Felt, measured, or meaningful

Three different things that get called the same word. Registered studies measured all three, and mixing them is how a blood test becomes a health claim.

Felt

Things a person could notice without a test.

  • adhd symptom severity based on the adhd rating scale
  • addiction research centre inventory
  • clinical global impression scale improvement
  • dichotomized clinical global impression effectiveness scale
  • clinical global impression severity
  • clinical global impression improvement

Measured

Things only a test, a scale or a device shows.

  • systolic blood pressure
  • diastolic blood pressure
  • maximum plasma concentration of guanfacine
  • time of maximum plasma concentration of guanfacine
  • time of plasma half life of guanfacine

Meaningful

Things that change how a life goes, not only a number.

No registered study measured anything of this kind.

A registered study says what someone planned to measure. It does not say what they found. A number moving is not the same as a life going better. The two are shown apart here.

Felt, but not shown to help. A person notices a change. No study showed it leads anywhere good.

Measured, but not felt. A number moves. The person notices nothing. Both can be true.

Measured, but not shown to matter. A number moves in the good direction. Nobody showed that lives went better.

Matters, but takes years. The result that counts may take longer than anyone would keep watching.

Names that fit none of the three (29)
  • retention
  • cocaine use
  • global improvement
  • cocaine withdrawal
  • cocaine related high
  • safety assessments
  • hyperactivity impulsiveness and distractibility
  • adhd rs
  • adhd rs total
  • aggression
  • improvement of adhd symptoms
  • apathy evaluation scale caregiver
  • side effects
  • cognitive test scores at end of treatment period
  • adhd iv rating scale
  • adhd symptoms
  • adverse drug reactions
  • discrimination effects assessed by operant responses
  • discrimination effects assessed by distribution
  • discrimination effects assessed by discrete choice

These are harms, study-process measures, or names the rules did not recognise. They are shown rather than dropped.

What it would be like to takeRead from sources, not yet reviewed

How long anything takes

Nine different lengths of time that get confused with each other. None of them is worked out from another.

  1. Before anything is noticed. RNAWiki does not store this separately, and never works it out from another figure on this page.

  2. Before a test result moves. RNAWiki does not store this separately, and never works it out from another figure on this page.

  3. Before performance moves. RNAWiki does not store this separately, and never works it out from another figure on this page.

  4. How long the result was watched. No finished study window is recorded for a study that tested this substance.

  5. How long people took it. How long people actually took it is not stored. The study window is not the same thing.

  6. How long people were followed. Follow-up length is not stored separately. It is never read off the study window, which would be a different thing.

  7. How fast the body clears it. 3.6 hours hours

    Read from the label, which states: “The mean half-life was about 3.6 hours.”

  8. How long effects linger. RNAWiki does not store this separately, and never works it out from another figure on this page.

  9. Beyond the studies. Nothing is recorded about the long term.

    The longest finished study sets the edge of what anyone measured.

A study window is not how long people took it, and neither is how long they were followed. Where RNAWiki holds only one of the three, it shows one.

What is missing or unclearRead from sources, not yet reviewed

Were people like you studied?

RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.

Who was studied

People similar to this profile were included.

  • Methylphenidate hydrochloride extended-release tablets are indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in children 6 years of age and older, adolescents, and adults up to the age of 65 [see Clinical Studies ( 14 )].

Who is missing from the studies

  • Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What the label states about particular groups

  • On pediatric, the label states: “Methylphenidate hydrochloride extended-release tablets should not be used in children under six years, since safety and efficacy in this age group have not been established.”

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

  • On older people, the label states: “Methylphenidate hydrochloride extended-release tablets has not been studied in patients greater than 65 years of age.”

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

  • On people who are pregnant, the label states: “The safety of methylphenidate for use during human pregnancy has not been established.”

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

  • On people who are breastfeeding, the label states: “It is not known whether methylphenidate is excreted in human milk.”

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

Where the result stopped carrying

  • This is a scope explorer, not a diagnosis engine.
  • It shows who was studied so you can see whether people similar to you were included.

RNAWiki cannot tell whether a study fits you. It can show who was in it.

What it would be like to takeRead from sources, not yet reviewed

Why it might seem to do nothing

A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.

It was studied for a different goal

The studies measured something else entirely.

On this record: Some registered studies measured things that match no goal on this page.

It was studied in different people

The people in the studies were not much like the reader.

On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

The evidence may simply be wrong

Small early studies often do not hold up.

On this record: RNAWiki has not yet published a reviewed conclusion for this use.

Other reasons RNAWiki checked and found nothing for (10)
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.

None of these is a reason to take more. Taking more is not a step this page ever suggests.

What it would be like to takeRead from sources, not yet reviewed

What taking it involves

The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.

How it is supplied

Prescription only

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Read from the recorded approval status.

No source is stored against this line.

Form and route

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form and route recorded on this substance.

No source is stored against this line.

Who oversees it

Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.

Quoted from a source

Where this came from

Copied from a source RNAWiki stored, with the source named.

Suppression classes recorded: S2, S6.

No source is stored against this line.

What is in the pack

Sold as capsule, extended release, for suspension, extended release, tablet, solution, given by the oral, transdermal route.

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

Recorded notes on how this is sold and what that means for what is in the pack.

No source is stored against this line.

Where it is registered

Regulatory records are listed in the technical disclosure at the foot of this page.

Counted from records

Where this came from

A count of rows RNAWiki holds. It describes our records, not your body.

Register entries are stored per jurisdiction and shown with their dates.

No source is stored against this line.

Why people stop

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

No record of why people stopped taking it is stored for this substance.

No source is stored against this line.

What it would be like to takeNothing found in the sources checked

What can go wrong

Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.

Nothing found in the sources checked

No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.

The sources listed were searched and held nothing. That is not the same as nothing existing.

Reports sent to a regulator

  • These are reports people sent to a regulator. They do not show the medicine caused the reaction.
  • Nobody counted how many people took the medicine and reported nothing.
  • The same event can be reported more than once, and many reports are incomplete.
  • News coverage, lawsuits and new warnings change how often people report.
  • A count is not a rate and not a risk.

Methylphenidate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 2141 reaction mentions were counted. One report can name several reactions.

The recorded terms (10)
  • toxicity to various agents — 351 reaction mentions
  • agitation — 262 reaction mentions
  • tachycardia — 257 reaction mentions
  • application site erythema — 228 reaction mentions
  • insomnia — 190 reaction mentions
  • aggression — 186 reaction mentions
  • hypertension — 186 reaction mentions
  • anxiety — 170 reaction mentions
  • decreased appetite — 170 reaction mentions
  • somnolence — 141 reaction mentions
  • open-targets-adr · recorded 2026-06-24 · a recorded source, not a stored snapshot

Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.

Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.

What is missing or unclearRead from sources, not yet reviewed

Does the exact form matter?

Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.

The form that was studied

Oral

Source-linked record

Where this came from

A person wrote this into the record with the study named beside it. No reviewer has signed it off.

The form used in the studies cited on this page.

No source is stored against this line.

What is sold

Not recorded.

Nothing recorded

Where this came from

RNAWiki holds nothing here and says so rather than guessing.

Nothing further is recorded about which forms are sold.

No source is stored against this line.

What is recorded as being sold

  • 306 products list this as an active ingredient in the United States drug directory. 306 of them contain it and nothing else.

    FDA National Drug Code directory · 72162-2041 · read 2026-08-29

  • They are sold as capsule, capsule, extended release, patch, powder, solution and suspension, extended release, taken oral and transdermal.

    FDA National Drug Code directory · 72162-2041 · read 2026-08-29

  • The regulator's established pharmacologic class for it is central nervous system stimulant [epc] and central nervous system stimulation [pe].

    FDA National Drug Code directory · 72162-2041 · read 2026-08-29

  • 87 published labels name it as an active ingredient. 87 of them describe this substance alone, which is where its own label text on this page comes from.

    US prescribing information · 213ca0da-dde8-48ee-ac8c-c66558e6f62d · read 2026-08-29

  • Those labels are classed as human prescription drug.

    US prescribing information · 213ca0da-dde8-48ee-ac8c-c66558e6f62d · read 2026-08-29

  • Methylphenidate Hydrochloride is oral at 3 DOSAGE FORMS AND STRENGTHS Methylphenidate hydrochloride extended-release tablets, USP are available in the following dosage strengths: Methylphenidate hydrochloride extended-release tablets USP, 18 mg are purple colo…, recorded as fda label in effect 2021-12-03 in the United States.

    US prescribing information · 7124df7e-6273-a68d-6e35-dc06122d8686 · read 2026-08-30

  • Recorded price in US: 0.07831–0.11891 USD per one millilitre, across 6 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

  • Recorded price in US: 0.13088–7.89039 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 55 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..

    Recorded source · 2026-08-26 · read 2026-08-28

Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.

What it would be like to takeRead from sources, not yet reviewed

What you could measure

This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.

Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.

Questions worth asking

  • Which of the trials of Methylphenidate studied people like me?
  • What was measured, and for how long?
  • Was the result a laboratory value or a health outcome?
  • What would we watch for, and when would we stop?

Tracking can show whether something changed for you. It cannot show what caused it.

RNAWiki records evidence. It does not say whether this substance is right for you.

What is missing or unclearRead from sources, not yet reviewed

What nobody knows yet

Open questions, each with why it is open and what would close it.

Missing populations

Which groups were under-represented in the studies has not been recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing long-term data

No completed tested study window is recorded.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

No reviewed conclusion

RNAWiki has not yet published a reviewed conclusion for this use.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Missing interaction studies

No interaction was found in the registers checked. Not finding one is not the same as showing there is none.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Formulation uncertainty

Several salts, forms or products of Methylphenidate are recorded. Results from one form may not transfer to another.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

Mechanism not reviewed

No reviewed mechanism story exists for this substance.

Why it matters. Recorded by the evidence model as a gap on this record.

What would answer it

A study that measures it, and a reviewer to sign it off.

Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.

What happened in peopleRead from sources, not yet reviewed

Check any of this yourself

Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.

How many documents were read

  • 86 documents were read for this substance.

    RNAWiki source record

  • 17 of them state the same proteinBinding, and they agree.

    RNAWiki source record

  • 52 of them state the same volumeOfDistribution, and they agree.

    RNAWiki source record

Where else this substance is registered

FDA substance identifier (UNII)
207ZZ9QZ49
CAS registry number
20748-11-2
ChEMBL
CHEMBL796
ChEBI
6887
WHO international nonproprietary name list entry
485
RxNorm concept
6901
EMA substance identifier
100000080907
European Chemicals Agency number
204-028-6
DrugBank
DB00422

Checks this page had to pass

  • Passed

    Identity resolved

    no open identity hold

  • Passed

    No unresolved merge across substance families

    no quarantine open

  • Passed

    Every public sentence names a source

    The opening statement carries the origin: Written into the record, not signed off.

  • Not passed

    Trial roles classified for highlighted evidence

    No registered study is classified as testing this substance.

  • Passed

    No internal keys in reader text

    enforced by the copy-contract test over the rendered page

  • Passed

    Safety mode resolved

    Suppression classes recorded: S2, S6.

  • Passed

    Canonical metadata present

    slug and display name present

What is missing or unclearRead from sources, not yet reviewed

How this medicine reached us

Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.

What the approval register records

  • 90 approved applications cover products containing this substance. The earliest was NDA010187, approved 19551205 to SANDOZ.

    Drugs@FDA application register · NDA010187 · read 2026-08-29

  • Marketing status on the register: discontinued, none (tentative approval) and prescription.

    Drugs@FDA application register · NDA010187 · read 2026-08-29

  • The earliest marketing start date recorded for a listed product is 19551231.

    FDA National Drug Code directory · 72162-2041 · read 2026-08-29

What is missing or unclearRead from sources, not yet reviewed

What to learn next

Ordered by what would most change how you read this page, starting with what is easiest to misunderstand.

This order is fixed in code and does not count clicks or time on the page.

What is not here

5 questions this page could not answer

These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.

  • The path through the body — found nothing in the sources checked.
  • What it may clash with — found nothing in the sources checked.
  • Other ways to the same goal — found nothing in the sources checked.
  • Claims that go past the evidence — found nothing in the sources checked.
  • What changed on this page — found nothing in the sources checked.

The record as stored

The full record, for auditing

Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.

Recorded evidence blocks (12)

What did Methylphenidate's largest trial (430000 people) and its longest (20 years) measure?


430000 people in Methylphenidate's largest registered study, 20 years in its longest registered window, measuring Peak Plasma Concentration of d-Methylphenidate. ClinicalTrials.gov · 2026-09-01

112 phase4, 78 phase3, 65 phase2, 54 na, 38 phase1, 22 na or unstated, 14 early phase1; NCT00483106; 2020-03-31; no ageing endpoint recorded. Last human test completed 2026, NCT07314333.

Interpretation These counts include studies where Methylphenidate was a comparison treatment, a background treatment or an exposure in an observational study, and the longest window may be a planned end date. Trial roles have not yet been classified for this record.

Show the evidence
  • phase4
    112
  • phase3
    78
  • phase2
    65
  • na
    54
  • phase1
    38
  • na or unstated
    22
2 more recorded rows
  • early phase1
    14
  • Last recorded human test NCT07314333
    2026-04-15

recorded 2026-09-01 · last checked 2026-09-04

From mouse to human: where has Methylphenidate shown biomarker?


mouse: mechanism-only and human: biomarker (363): the rungs where Methylphenidate has a recorded finding. Europe PMC and ClinicalTrials.gov · organism ladder · 2026-09-01

Interpretation Peak Plasma Concentration of d-Methylphenidate — the recorded outcome words.

Yeast C. elegans Drosophila Mouse mechanism-onlyRat Dog Non-human primate Human biomarker
Show the evidence
  • mouse
    mechanism-only
  • human NCT00302458
    biomarker; Peak Plasma Concentration of d-Methylphenidate; 363

recorded 2026-09-01 · last checked 2026-09-04

28 of Methylphenidate's trials stopped: safety, accrual/recruitment, funding/business, sponsor decision unspecified, other?


safety (3), accrual/recruitment (15), funding/business (2), sponsor decision unspecified (1) and other (7): Methylphenidate's stop wording, clustered. ClinicalTrials.gov · 2026-09-01

"low accrual; loss of funding"; 28 of 363 registered studies

Show the evidence

Trial

  • NCT00031798
    terminated; "low accrual; loss of funding"
  • NCT00069927
    terminated; "Only 12 subjects enrolled. DSMB recommended closing due to lack of feasibility"
  • NCT00273741
    terminated; "difficulty of recrutement"
  • NCT00393562
    withdrawn; "Unable to recruit any subjects for this study"
  • NCT00396058
    terminated; "Recruitment of patients proved much too difficult based on the chosen criteria."
  • NCT00418691
    terminated; "Closed early due to slow accrual."
14 further recorded trials
  • NCT00516269
    terminated; "Slow Accrual"
  • NCT00593853
    terminated; "Slow Accrual"
  • NCT00599287
    terminated; "Inclusion rate too low due to a lack of eligible patients and difficulties obtaining informed consent."
  • NCT00792662
    withdrawn; "No Subjects enrolled"
  • NCT00931398
    withdrawn; "Study was not initiated due to lack of funding by the sponsor"
  • NCT01100658
    terminated; "Due to slow accrual"
  • NCT01164956
    terminated; "Insufficient Resources"
  • NCT01244269
    terminated; "Inadequate enrolment, protocol too challenging for participants, lack of observable benefit after analysis of 6 patients."
  • NCT01348607
    terminated; "Study only randomized 1 subject and was determined not feasible by DSMB"
  • NCT01416948
    terminated; "The funding agency, DoD, determined that the study could not meet its enrollment numbers by the end of the grant."
  • NCT01773837
    terminated; "Slow accrual. 100 patients included"
  • NCT01825577
    terminated; "Administrative Reasons"
  • NCT02063945
    terminated; "Major difficulties recruiting participants"
  • NCT02148783
    terminated; "Recruitment was slower than anticipated. Incomplete neuropsychological outcome measures obtained."

recorded 2026-09-01 · last checked 2026-09-04

Human studies of Methylphenidate used Methylphenidate 20 mg long-acting capsules — over how long?


studies of Methylphenidate used the recorded amount. ClinicalTrials.gov · 2026-09-01

15 recorded entries; human; tablet; also "Methylphenidate 20 mg long-acting capsules", "Methylphenidate 40 mg", "Ritalin LA 20 mg"

Show the evidence

human

  • NCT00428792
    Methylphenidate 20 mg long-acting capsules
  • NCT01218425
    Methylphenidate 40 mg
  • NCT01259492
    Ritalin LA 20 mg
  • NCT01259492
    Ritalin LA 30 mg
  • NCT01416948
    Methylphenidate Hydrochloride 20 mg
  • NCT01879202
    Ritalin LA 20mg
9 more recorded rows
  • human NCT01879202
    Ritalin LA 30mg
  • human NCT01879202
    Ritalin LA 40mg
  • human NCT02071615
    tablet; Methylphenidate 20 mg tablet given once by mouth
  • human NCT02265718
    tablet; methylphenidate hydrochloride 20mg tablet taken once on day 0 and once on day 28
  • human NCT03190681
    Ritalin (methylphenidate)10Mg Tablet
  • human NCT03515668
    Ritalin 20 mg Tablet
  • human NCT03769064
    Methylphenidate 60 mg
  • human NCT04968522
    Methylphenidate Hydrochloride 18 MG
  • human NCT05272397
    Methylphenidate 20 Mg Oral Tablet

recorded 2026-09-01 · last checked 2026-09-04

More Methylphenidate was worse in human: at what point?


U-shaped in human: "Finally, for methylphenidate and lisdexamphetamine, we found evidence of U-shaped associations between doses used and risks of all-cause hospitalization/mortality and psychosis." Europe PMC · dose-response search · 2025-07-01

5 recorded sentences naming Methylphenidate; U-shaped, dose-response, biphasic

Show the evidence
  • U-shaped PMID 40595332
    "Finally, for methylphenidate and lisdexamphetamine, we found evidence of U-shaped associations between doses used and risks of all-cause hospitalization/mortality and psychosis."
  • dose-response PMID 38348853
    "The aim of this study was to use 'real-world' data to evaluate the effect and side effects of using methylphenidate in palliative cancer care with a focus on the late palliative phase and dose-response."

biphasic

  • PMID 31786618
    "In all subjects, d-threo-methylphenidate was detectable in plasma for at least 15 h after the dose with a biphasic profile. l-threo-Methylphenidate was measurable in only five subjects and in most cases in low concentrations."
  • PMID 31786618
    "However, one female subject displayed a biphasic concentration-time profile for l-threo-methylphenidate."
  • PMID 31786618
    "In eleven subjects, dl-threo-methylphenidate in oral fluid mirrored the biphasic profile of methylphenidate (sum of d- and l-threo-enantiomers) in plasma, but the concentrations in oral fluid were on average 1.8 times higher than in plasma. dl-threo-Methylphenidate was detected in exhaled breath in all subjects, but there was no consistent concentration-time pattern."

recorded 2025-07-01 · last checked 2026-09-04

Methylphenidate's half-life is 3.6 hours — which schedules were studied?


3.6 hours, the half-life Methylphenidate's label states. openfda-label · e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 · 2026-08-30

Show the evidence
  • half life
    3.6 hours hours; The mean half-life was about 3.6 hours.
  • bioavailability
    Absorption The absolute oral bioavailability of methylphenidate in children was 22 ± 8% for d-methylphenidate and 5 ± 3% for l- methylphenidate.
  • metabolism
    Metabolism The absolute oral bioavailability of methylphenidate in children was 22 ± 8% for d-methylphenidate and 5 ± 3% for l- methylphenidate, suggesting pronounced presystemic metabolism.

recorded 2026-08-30 · last checked 2026-09-04

Which of addiction research centre inventory, adhd iv rating scale and adhd rs did Methylphenidate's trials measure?


addiction research centre inventory, adhd iv rating scale and adhd rs lead 40 outcome terms across Methylphenidate's trials. ClinicalTrials.gov · 2026-09-01

Interpretation cocaine withdrawal, cocaine related high, safety assessments, hyperactivity impulsiveness and distractibility, adhd symptom severity based on the adhd rating scale and adhd rs follow.

Show the evidence
  • retention
    1
  • cocaine use
    1
  • global improvement
    1
  • cocaine withdrawal
    1
  • cocaine related high
    1
  • safety assessments
    1
14 more recorded rows
  • hyperactivity impulsiveness and distractibility
    1
  • adhd symptom severity based on the adhd rating scale
    1
  • adhd rs
    1
  • adhd rs total
    1
  • aggression
    1
  • improvement of adhd symptoms
    1
  • addiction research centre inventory
    1
  • apathy evaluation scale caregiver
    1
  • side effects
    1
  • cognitive test scores at end of treatment period
    1
  • adhd iv rating scale
    1
  • adhd symptoms
    1
  • adverse drug reactions
    1
  • discrimination effects assessed by operant responses
    1

recorded 2026-09-01 · last checked 2026-09-04

Which of Methylphenidate's 42 ongoing trials reports first?


42 registered trials of Methylphenidate are open; earliest completion 2025-03-25. ClinicalTrials.gov · 2026-09-01

Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale scores; Pittsburgh Sleep Quality Index (PSQI) Score Change; latest 2031-08-31

Show the evidence

Trial

  • NCT01410942
    "Multimodal Therapy for the Treatment of Fatigue in Patients With Prostate Cancer Receiving Radiotherapy With Androgen Deprivation Therapy"; n 175; "Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale scores"; 2026-09-30
  • NCT01628029
    "Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer"; n 68; "Pittsburgh Sleep Quality Index (PSQI) Score Change"; 2028-12-31
  • NCT03420339
    "Stimulant Effects on Disruptive Behavior"; n 10; "Change in Behavioral Function"; 2027-08-01
  • NCT03511118
    "Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants"; n 1600; "M/P ratio"; 2028-07-31
  • NCT03525873
    "A Study of Cancer Related Fatigue in Patients With Metastatic Cancer Receiving Anti-PD1 Immunotherapy"; n 212; "Assessment of the effects of methylphenidate (MP) plus physical activity in reducing cancer-related fatigue (CRF)"; 2026-12-31
  • NCT03772834
    "Methylphenidate and Exercise in Reducing Cancer-Related Fatigue in Patients With Prostate Cancer"; n 200; "Level of cancer-related fatigue in all groups"; 2026-11-30
14 further recorded trials
  • NCT03814356
    "Stimulant Therapy Targeted to Individualized Connectivity Maps to Promote ReACTivation of Consciousness"; n 10; "Number of Participants With Adverse Events at Each Dose"; 2026-06-30
  • NCT04219280
    "Evaluating Treatment of ADHD in Children With Down Syndrome"; n 100; "Mean magnitude of change in ADHD Symptoms as measured by parent and teacher report on the Vanderbilt ADHD Parent and Teacher Rating Scales, compared to placebo, during the optimal MPH dosage period. [ Time Frame: Phase 2, Phase 3 ]"; 2026-08-31
  • NCT04419272
    "Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits"; n 226; "Change in Conners Continuous Performance Test (CPT), Following Placebo vs. Methylphenidate"; 2028-05-31
  • NCT04421248
    "Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder"; n 214; "Transcranial Magnetic Stimulation (TMS)-evoked Short Interval Cortical Inhibition (SICI) Test-Retest Reliability"; 2026-07-01
  • NCT04781972
    "Multimodal Brain Imaging of the Neural Effects of Methylphenidate in Patients With ADHD"; n 30; "BOLD signal during response inhibition"; 2029-04-30
  • NCT05133804
    "Efficacy of Reboxetine and Methylphenidate Treatment on Attentional, Sensory and Emotional Dysregulation in Adults With PTSD"; n 53; "Change in Clinician-Administered Posttraumatic Stress Disorder Scale for the Diagnostic and Statistical Manual (DSM)-5 (CAPS-5) between baseline score (before treatment) and score on day 26 (after treatment)"; 2026-12-01
  • NCT05285683
    "The Role of Brain Dopamine in Chronic Pain"; n 10; "mean change in amygdala volume"; 2027-12-22
  • NCT05301361
    "Sensitivity of the NIH Toolbox to Stimulant Treatment in Intellectual Disabilities"; n 68; "Composite score of NIHTB-CB Flanker, Dimensional Change Card Sort, List Sorting and Speeded Matching tests."; 2026-09-29
  • NCT05474846
    "Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer"; n 188; "Pittsburgh Sleep Quality Index (PSQI) questionnaires"; 2027-02-28
  • NCT05536011
    "WAKIX® (Pitolisant) Pregnancy Registry"; n 1329; "Major congenital malformation"; 2030-06-30
  • NCT05561205
    "rTMS for Apathy Clinical Trial"; n 10; "Neuropsychiatric Inventory-apathy"; 2026-12-01
  • NCT05600881
    "Towards an Understanding of the Mechanism of Action of Methylphenidate in ADHD"; n 35; "MRI"; 2026-09
  • NCT05630781
    "Orexin s Role in the Neurobiology of Substance Use Disorder"; n 140; "fMRI - cue reactivity"; 2027-12-31
  • NCT05669170
    "Methylphenidate for Apathy in Veterans With Parkinson's Disease"; n 60; "Apathy Evaluation Scale (AES)"; 2028-06

recorded 2026-09-01 · last checked 2026-09-04

Which 134 trials of Methylphenidate posted no result?


Posted no result
134 of 134 completed trials
Registrations
NCT00693212, NCT00269789, NCT00269776, NCT00269802, NCT00015223 and NCT00015054, and 128 more
Completion dates
oldest 1994-11; newest 2024-04-26
Show the evidence

Trial

  • NCT00693212
    1994-11
  • NCT00269789
    1998-05
  • NCT00269776
    1999-01
  • NCT00269802
    1999-02
  • NCT00015223
    1999-08
  • NCT00015054
    1999-11
14 further recorded trials
  • NCT00269815
    1999-12
  • NCT00012584
    2002-05
  • NCT00381758
    2002-08
  • NCT00249353
    2002-10
  • NCT00136734
    2004-03
  • NCT00061087
    2004-10
  • NCT00486083
    2004-10
  • NCT00663442
    2004-11
  • NCT00824317
    2005-02
  • NCT00485550
    2005-03
  • NCT00466791
    2005-05
  • NCT00444574
    2005-06
  • NCT00015301
    2005-08
  • NCT00181987
    2005-08

At the median, Methylphenidate's trials enrolled 48 people — anything larger?


Median enrolment
48
Largest enrolment
430000
Registered trials counted
356

What do 2141 spontaneous reports say about Methylphenidate — and not say?


These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.

Methylphenidate appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 2141 reaction mentions were counted: toxicity to various agents 351; agitation 262; tachycardia 257; application site erythema 228. open-targets-adr · CHEMBL796 · 2026-06-24

Show the evidence
  • toxicity to various agents
    351
  • agitation
    262
  • tachycardia
    257
  • application site erythema
    228
  • insomnia
    190
  • aggression
    186
4 more recorded rows
  • hypertension
    186
  • anxiety
    170
  • decreased appetite
    170
  • somnolence
    141

recorded 2026-06-24 · last checked 2026-09-04

Was Methylphenidate studied with fasting and exercise?


fasting and exercise are named in Methylphenidate's label sentences: "We conducted an open-label, single-dose, randomized, crossover study in healthy adults to assess the impact of food on the bioavailability of 60 mg methylphenidate extended-release oral suspension (MEROS; Quillivant XR™)-a long-acting stimulant for the treatment of attention deficit hyperactivity…" openfda-label+europepmc · 2017-06-19

2 recorded statements; fasting, exercise

Show the evidence
  • fasting
    We conducted an open-label, single-dose, randomized, crossover study in healthy adults to assess the impact of food on the bioavailability of 60 mg methylphenidate extended-release oral suspension (MEROS; Quillivant XR™)-a long-acting stimulant for the treatment of attention deficit hyperactivity disorder-by comparing the pharmacokinetic parameters under fed and fasting conditions.
  • exercise
    Subjects ingested either placebo (PLA; 20 mg) or methylphenidate (MPH; Ritalin; 20 mg) 1 h before the start of exercise in temperate (18 degrees C) or warm (30 degrees C) conditions and cycled for 60 min at 55% Wmax, immediately followed by a time trial (TT; PLA18 and MPH18; PLA30 and MPH30) to measure exercise performance.

recorded 2017-06-19 · last checked 2026-09-04

Where it is registered
Identifiers, relations and other names

The exact record

ChEMBL id
CHEMBL796
CAS number
20748-11-2
RxCUI
6901
InChIKey
DUGOZIWVEXMGBE-UHFFFAOYSA-N
Salt form
Methylphenidate Hydrochloride, Methylphenidate HCl, methylphenidate hydrochloride CD, Methylphenidate Hydrochloride Extended-Release, Methylphenidate Hydrochloride / Metadate Cd / Ritalin / Relexxii / Methylphenidate Hydrochloride (La) / Methylin
Trade name
Metadate Cd, Ritalin, Relexxii, Methylin, CONCERTA, Daytrana, Cotempla XR-ODT, Methylphenidate Extended-Release, QuilliChew ER, Quillivant XR, Ritalin LA, JORNAY PM Extended-Release
Also called
2-PIPERIDINEACETIC ACID, .ALPHA.-PHENYL-, METHYL ESTER, METHYLPHENIDATE [HSDB], METHYLPHENIDATE [II], METHYLPHENIDATE [MART.], METHYLPHENIDATE [MI], METHYLPHENIDATE [ORANGE BOOK], METHYLPHENIDATE [USAN], METHYLPHENIDATE [VANDF]
Sources (10)

Sources

4 more sources
  • open-targets-adr CHEMBL796 ·
  • openfda-label e5db854a-1c77-4faf-9e60-daf9c9b6cfa0 ·
  • openfda-label+europepmc HOLD:existing:methylphenidate ·
  • national registers US, EU, CA ·

ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Europe PMC — metadata only, under the recorded legal gate · Open Targets 26.06 — CC0 · derived from this page's own recorded fields; no external licence · mixed register set; per-register licences in docs/specs/corpus-20k-sources.md · openFDA / DailyMed — US Government work

How these records are assembled · Which registers were checked

Index-quality checks
  • identity passed: no open identity hold
  • required summary fields resolved: 5 required field(s) not terminal: Why people use it, Best-supported result, Most important common problem, Biggest unanswered question, Human evidence
  • public claims reviewed: 0 reviewed claim(s); drafts are never rendered
  • source coverage passed: 10 source rows
  • no critical contamination: no quarantine open
  • canonical metadata passed: slug and display name present
  • no raw internal fields: enforced by the copy-contract test over the rendered page

This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.